Apoptosis of human prostate androgen-dependent and -independent carcinoma cells induced by an isopropanolic extract of black cohosh involves degradation of cytokeratin (CK) 18

Anticancer Research

Volumn 25, Issue 1 A, 2005, Pages 139-147

  Hostanska, Katarina ^a   Nisslein, Thomas ^b   Freudenstein, Johannes ^b   Reichling, Juergen ^c   Saller, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Schaper & Brummer GmbH & Co KG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Annexin V FITC; Apoptosis; Black cohosh extract; M30 antibody; Prostate cancer cells

Indexed keywords

2 PROPANOL; ANDROGEN; ANNEXIN; CASPASE; CIMICIFUGA RACEMOSA EXTRACT; CYTOKERATIN 18; ESTRADIOL; FLUORESCEIN ISOTHIOCYANATE; GENISTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M30; STAUROSPORINE; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL GROWTH; CELL PROLIFERATION; CIMICIFUGA RACEMOSA; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; ENZYME ACTIVATION; GROWTH INHIBITION; HORMONE DEPENDENCE; HORMONE RESPONSE; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; INHIBITION KINETICS; MEDICINAL PLANT; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DEGRADATION;

2-PROPANOL; ANDROGENS; APOPTOSIS; CASPASES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CIMICIFUGA; ENZYME INDUCTION; HUMANS; KERATINS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC NEOPLASMS;

EID: 16344364309     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Aus G, Adolfsson J, Selli C and Widmark A: Treatment of patients with clinical T3 prostate cancer. Scand J Urol Nephrol 36: 28-33, 2002.
2. Lynn AG and Ries MS: Stat Bite: Top 5 cancers for females and males in the U.S. JNCI 87: 867, 1995.
3. Palmberg C, Koivisto P, Visakorpi T and Tammela T: PSA is an independent prognostic marker in hormonally treated prostate cancer. Eur Urol 36: 191-196, 1999.
4. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schroder FH and van der Kwast TH: Androgen receptors status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144: 735-746, 1994.
5. Denmeade SR and Isaacs JT. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. Adv Pharmacol 35: 281-306, 1996.
6. McConkey DJ, Greene G and Pettaway CA: Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 56: 5594-5599, 1996.
7. Lotan R: Retinoids and apoptosis: implications for cancer chemoprevention and therapy. JNCI 87: 1655-1657, 1995.
8. Martikainen P, Kyprianou N, Tucker RW and Isaacs JT: Programmed death of nonproliferating and androgen-independent prostatic cancer cells. Cancer Res 51: 4693-4701, 1991.
9. Kyprianou N, Bains A and Jacobs S: Induction of apoptosis in androgen-independent human prostate cancer cells undergoing thymineless death. Prostate 25: 66-75, 1994.
10. Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N and English HF: Androgen regulation of programmed death of normal and malignant prostatic cells. J Anrol 13: 457-464, 1992.
11. Landstrom M, Bergh A, Tomic R and Damber JE: Estrogen treatment combined with castration inhibits tumor growth more effectively than castration alone in the Dunning R-3327 rat prostatic adenocarcinoma. Prostate 17: 57-68, 1990.
12. Raghavan D: Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol 15: 371-389, 1988.
13. Lieberman S: A review of the effectiveness of Cimicifuga racemosa (Black Cohosh) for the symptoms of menopause. J Women's Health 7: 525-529, 1998.
14. Liske E: Therapeutic efficacy and safety of Cimicifuga racemosa for gynecologic disorders. Adv Natural Ther 15: 45-53, 1998.
15. Jarry H, Harnischfeger G and Düker E: Studies on the endocrine effects of the contents of Cimicifuga racemosa, 11: in vitro binding of compounds to estrogen receptors. Planta Med 4: 316-319, 1985.
16. Zava DT, Dollbaum CM and Blen M: Estrogen and progestin bioactivity of foods, herbs, and spices. Proc Soc Exp Biol Med 217: 369-378, 1998.
17. Liu J, Burdette JE, Xu H, Gu C, van Breemen RB, Bhat KP, Booth N, Constantinou Al, Pezzuto JM, Fong HH, Famsworth NR and Bolton JL: Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem 49: 2472-2479, 2001.
18. Beck V, Unterrieder E, Krenn L, Kubelka W and Jungbauer A: Comparison of hormonal activity (estrogen, androgen and progestin) of standardized plant extracts for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 84: 259-268, 2003.
19. Seidlova-Wuttke D, Hesse O, Jarry H, Christoffel V, Spengler B, Becker T and Wuttke W: Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17 beta. Eur J Endocrinol 149: 351-362, 2003.
20. Nisslein T and Freudenstein J: Effects of an isopropanolic extract of Cimicifuga racemosa on urinary crosslinks and other parameters of bone quality in an ovariectomized rat model of osteoporosis. J Bone Miner Metab 21: 370-376, 2003.
21. Zierau O, Bodinet C, Kolba S, Wulf M and Vollmer G: Antiestrogenic activities of Cimicifuga racemosa extracts. J Steroid Biochem Mol Biol 80: 125-130, 2002.
22. Bodinet C and Freudenstein J: Influence of Cimicifuga racemosa on the proliferation of estrogen receptor-positive human breast cancer cells. Breast Cancer Res Treat 76: 1-10, 2002.
23. Hostanska K, Nisslein T, Freudenstein J, Reichling J and Saller R: Cimicifuga racemosa extract inhibits proliferation of estrogen receptor-positive and negative human breast carcinoma cell lines by induction of apoptosis. Breast Cancer Res Treat 84: 151-160, 2004.
24. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y and Ueno K: A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 1: 1518-1520, 1996.
25. Bruggisser R, von Daeniken K, Jundt G, Schaffner W and Tullberg-Reinert H: Interference of plant extracts, phytoestrogens and antioxidants with the MTT tetrazolium assay. Planta Med 68: 445-448, 2002.
26. Vermes I, Haanen C and Steffens-Nakken H: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Meth 184: 39-51, 1995.
27. Perry RR, Kang Y and Greaves B: Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 2: 238-245, 1995.
28. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A and Bhalla K: Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 42: 73-81, 1997.
29. Cappelletti V, Fioravanti L, Miodini P and Di Fronzo G: Genistein blocks breast cancer cells in the G(2)M phase of the cell cycle. J Cell Biochem 79: 594-600, 2000.
30. Leers MP, Kölgen W, Björklund V, Bergman T, Tribbick G, Persson B, Björklund P, Ramaekers FCS, Björklund B, Nap M, Jörnvall H and Schutte B: Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187: 567-572, 1999.
31. Webber MM, Bello D and Quader S: Immortalized and tumorigenic adult human prostatic epithelial cell lines. Characteristics and applications. Part 2. Tumorigenic cell lines. Prostate 30: 58-64, 1997.
32. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ and Lucia MS: Molecular characterization of human prostate carcinoma cell lines. Prostate 57: 205-225, 2003.
33. Santti R, Newbold RR, Mäkelä S, Pylkkänen L and McLachlan JA: Developmental estrogenization and prostatic neoplasia. Prostate 24: 67-78, 1994.
34. International Prostate Health Council Study Group. Estrogens and prostatic disease. Prostate 45: 87-100, 2000.
35. Linja MJ, Savinainen KJ, Tammela TLJ, Isola JJ and Visakorpi T: Expression of ERα and ERβ in prostate cancer. Prostate 55: 180-186, 2003.
36. Tang DG and Porter AT: Target to apoptosis: A hopeful weapon for prostate cancer. Prostate 32: 284-293, 1997.
37. Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS and Blomme EA: Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 199: 221-228, 2003.
38. Kumi-Diaka J, Sanderson NA and Hall A: The mediating role of caspase-3 protease in the intracellular mechanism of genistein-induced apoptosis in human prostatic carcinoma cell lines, DU 145 and LNCaP. Biol Cell 92: 595-604, 2000.
39. Carroll AG, Voeller HJ, Sugars L and Gelmann EP: p53 oncogene mutations in three human prostate cancer cell lines. Prostate 23: 123-134, 1993.
40. Li X, Marani M, Mannucci R, Kinsey B, Andriani F, Nicoletti I, Denner L and Marcelli M: Overexpression of BCL-X(L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res 61: 1699-1706, 2001.
41. Coffey RNT, Watson RWG, Hegarty PK, Watson CL, Wolohan L, Brady HR, O'Keane C and Fitzpatrick JM: Priming prostate carcinoma cells for increased apoptosis is associated with upregulation of the caspases. Cancer 92: 2297-2308, 2001.
42. Chen SN, Li W, Fabricant DS, Santarsiero BD, Mesecar A, Fitzloff JF, Fong HH and Farnsworth NR: Isolation, structure elucidation, and absolute configuration of 26-deoxyactein from Cimicifuga racemosa and clarification of nomenclature associated with 27-deoxyactein. J Natl Prod 65: 601-605, 2000.
43. Li W, Sun Y, Liang W, Fitzloff JF and van Breemen RB: Identification of caffeic acid derivates in Actea racemosa (Cimicifuga racemosa, black cohosh) by liquid chromatography/tandem mass spectometry. Rapid Commun Mass Spectrom 17: 978-982, 2003.
44. Watanabe K, Mimaki Y, Sakagami H and Sashida Y: Cycloartane glycosides from the rhizomes of Cimicifuga racemosa and their cytotoxic activities. Chem Pharm Bull 50: 121-125, 2002.
45. Einbond LS, Shimizu M, Xiao D, Nuntanakorn P, Lim JTE, Suzui M, Seter C, Pertel T, Kennelly EJ, Kronenberg F and Weinstein IB: Growth inhibitory activity of extract and purified components of black cohosh on human breast cancer cells. Breast Cancer Res Treat 83: 221-231, 2004.
46. Sakurai N, Kozuba M, Tokuda H, Nobukuni Y, Takayasu J, Nishino H, Kusano A, Kusano G, Nagai M, Sakurai Y and Lee K: Antitumor agents 220. Antitumor-promoting effects of cimigenol and related compounds on Epstein-Barr virus activation and two-stage mouse skin carcinogenesis. Bioorg Med Chem 11: 1137-1140, 2003.
47. Sakurai N, Wu JH, Sachida Y, Mimaki Y, Nikaido T, Koike K, Itikawa H and Lee KH: Anti-AIDS agent. Part 57: Actein, an anti-HIV principle from the rhizome of Cimicifuga racemosa (black cohosh), and the anti-HIV activity of related saponins. Bioorg Med Chem 14: 1329-1332, 2004.